ibrutinib combination therapy in cll: overview of the data so far
Published 6 years ago • 146 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
3:28
overview of 3 studies on cll therapy: data on ibrutinib and a ror1 inhibitor
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:56
emerging ibrutinib-based combinations in cll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
1:28
overview of resonate-2 clinical trial of ibrutinib in cll
-
1:47
ianalumab add-on therapy in cll patients receiving ibrutinib
-
6:48
patient selection for treatment with ibrutinib in cll
-
7:13
using ibrutinib in chronic lymphocytic leukemia (cll)
-
5:59
6-year results of cll14: venetoclax-obinutuzumab for previously untreated cll
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
1:49
venetoclax in combination with ibrutinib: can it control cll?
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
2:18
first-line ibrutinib and venetoclax in cll
-
1:50
targeted therapy in cll in 2022 and in the future
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
9:00
overview of cll therapies and sequencing of therapies
-
1:38
front-line use of ibrutinib for cll in a real-world setting
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
2:02
enhancing immunotherapy for cll patients with ibrutinib